The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the branch of the National Institutes of Health (NIH) that focuses on funding research related to FSGS, Nephrotic Syndrome, and other kidney diseases. In 2016, they funded $574 million worth of research projects, and they continue to be a leader in clinical trials.
Currently, there are two clinical trials being held at the NIDDK that are relevant to the Nephrotic Syndrome community:
- Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- Goal of the study: To determine the safety and effectiveness of combining rituximab and cyclosporine to treat membranous nephropathy
- Eligibility: Individuals 18 years of age and older who have been diagnosed with membranous nephropathy based on a kidney biopsy done within the preceding 24 months, and who have had excess levels of protein in the urine for at least 6 months based on urine and blood tests.
- Immune System Related Kidney Disease
- Goal of the study: This study will provide information about the causes and specific abnormalities associated with autoimmune kidney disease
- Eligibility: Adults and children with immunologically-mediated renal diseases, proven or suspected.
- Genetic Markers for Focal Segmental Glomerulosclerosis
- Goal of the study: To develop a molecular understanding of racial differences in the incidence of podocyte diseases
- Eligibility: Individuals (adults and children) of African-descent with FSGS: renal biopsy showing FSGS or collapsing glomerulopathy, including HIV-associated collapsing glomerulopathy (HIV-associated nephropathy).
You can learn more about these clinical trials and other opportunities by using our clinical trial finder, called Antidote.